Skip to main content
Log in

Clinical Implications of the CAMIAT, EMIAT and SWORD Trials: A South American Perspective

  • Published:
Cardiac Electrophysiology Review

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for GESICA. Randomized trial of low-dose amiodarone in severe heart failure. Lancet 1994;344:493-498.

    Google Scholar 

  2. Singh SN, Fletcher RD, Fisher SG, et al., for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.

    Google Scholar 

  3. Nul DR, Doval HC, Grancelli HO, et al., on behalf of the GESICA-GEMA investigators. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997;29:1199-1205.

    Google Scholar 

  4. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6,500 patients in randomized trials. Lancet 1997;350:1417-1424.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doval, H.C. Clinical Implications of the CAMIAT, EMIAT and SWORD Trials: A South American Perspective. Card Electrophysiol Rev 2, 36–37 (1998). https://doi.org/10.1023/A:1009938306576

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009938306576

Keywords

Navigation